Literature DB >> 31444470

Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction.

Keiichiro Suzuki1,2,3, Mako Yamamoto4, Reyna Hernandez-Benitez4, Zhe Li5, Christopher Wei5, Rupa Devi Soligalla4,6, Emi Aizawa4,7, Fumiyuki Hatanaka4, Masakazu Kurita4,6, Pradeep Reddy4, Alejandro Ocampo4, Tomoaki Hishida4, Masahiro Sakurai4,6, Amy N Nemeth4, Estrella Nuñez Delicado6, Josep M Campistol8, Pierre Magistretti9, Pedro Guillen10, Concepcion Rodriguez Esteban4, Jianhui Gong11,12,13,14, Yilin Yuan11,12,13, Ying Gu11,12,13, Guang-Hui Liu15, Carlos López-Otín16, Jun Wu6,17,18, Kun Zhang5, Juan Carlos Izpisua Belmonte19.   

Abstract

In vivo genome editing represents a powerful strategy for both understanding basic biology and treating inherited diseases. However, it remains a challenge to develop universal and efficient in vivo genome-editing tools for tissues that comprise diverse cell types in either a dividing or non-dividing state. Here, we describe a versatile in vivo gene knock-in methodology that enables the targeting of a broad range of mutations and cell types through the insertion of a minigene at an intron of the target gene locus using an intracellularly linearized single homology arm donor. As a proof-of-concept, we focused on a mouse model of premature-aging caused by a dominant point mutation, which is difficult to repair using existing in vivo genome-editing tools. Systemic treatment using our new method ameliorated aging-associated phenotypes and extended animal lifespan, thus highlighting the potential of this methodology for a broad range of in vivo genome-editing applications.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31444470      PMCID: PMC6796851          DOI: 10.1038/s41422-019-0213-0

Source DB:  PubMed          Journal:  Cell Res        ISSN: 1001-0602            Impact factor:   25.617


  15 in total

Review 1.  Correction of muscular dystrophies by CRISPR gene editing.

Authors:  Francesco Chemello; Rhonda Bassel-Duby; Eric N Olson
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  Efficient targeted insertion of large DNA fragments without DNA donors.

Authors:  Jinlin Wang; Zhou He; Guoquan Wang; Ruiwen Zhang; Junyi Duan; Pan Gao; Xinlin Lei; Houyuan Qiu; Chuanping Zhang; Ying Zhang; Hao Yin
Journal:  Nat Methods       Date:  2022-02-28       Impact factor: 47.990

3.  Co-opting regulation bypass repair as a gene-correction strategy for monogenic diseases.

Authors:  Jingjie Hu; Rebecca A Bourne; Barbara C McGrath; Alice Lin; Zifei Pei; Douglas R Cavener
Journal:  Mol Ther       Date:  2021-04-21       Impact factor: 11.454

4.  Full-length dystrophin restoration via targeted exon integration by AAV-CRISPR in a humanized mouse model of Duchenne muscular dystrophy.

Authors:  Adrian Pickar-Oliver; Veronica Gough; Joel D Bohning; Siyan Liu; Jacqueline N Robinson-Hamm; Heather Daniels; William H Majoros; Garth Devlin; Aravind Asokan; Charles A Gersbach
Journal:  Mol Ther       Date:  2021-09-10       Impact factor: 12.910

5.  In vivo base editing rescues Hutchinson-Gilford progeria syndrome in mice.

Authors:  Luke W Koblan; Michael R Erdos; Christopher Wilson; Wayne A Cabral; Jonathan M Levy; Zheng-Mei Xiong; Urraca L Tavarez; Lindsay M Davison; Yantenew G Gete; Xiaojing Mao; Gregory A Newby; Sean P Doherty; Narisu Narisu; Quanhu Sheng; Chad Krilow; Charles Y Lin; Leslie B Gordon; Kan Cao; Francis S Collins; Jonathan D Brown; David R Liu
Journal:  Nature       Date:  2021-01-06       Impact factor: 49.962

Review 6.  Genome editing technologies: CRISPR, LEAPER, RESTORE, ARCUT, SATI, and RESCUE.

Authors:  Senay Görücü Yilmaz
Journal:  EXCLI J       Date:  2021-01-04       Impact factor: 4.068

Review 7.  Therapeutic genome editing in cardiovascular diseases.

Authors:  Masataka Nishiga; Lei S Qi; Joseph C Wu
Journal:  Adv Drug Deliv Rev       Date:  2020-02-21       Impact factor: 15.470

Review 8.  Genome Editing for CNS Disorders.

Authors:  Fábio Duarte; Nicole Déglon
Journal:  Front Neurosci       Date:  2020-10-22       Impact factor: 4.677

Review 9.  Use of Customizable Nucleases for Gene Editing and Other Novel Applications.

Authors:  Pradeep Reddy; Felipe Vilella; Juan Carlos Izpisua Belmonte; Carlos Simón
Journal:  Genes (Basel)       Date:  2020-08-22       Impact factor: 4.096

Review 10.  Treating primary immunodeficiencies with defects in NK cells: from stem cell therapy to gene editing.

Authors:  C Eguizabal; L Herrera; M Inglés-Ferrándiz; J C Izpisua Belmonte
Journal:  Stem Cell Res Ther       Date:  2020-10-27       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.